Presentation Sponsor
Sponsorship
For Sponsorship Opportunities, Please Contact
Anna Zhu
Tel: +86-21-61573916
Mobile: 13585534152
Email: Haiyan.Zhu@ubm.com
Supported By
Organised By

Follow Us:


Speakers:
 
 
Qingkui Zhang
Qingkui Zhang
Former Director General, Pharmaceutical and Biotech Examination Department
State Intellectual Property Office (SIPO)
Hongqiang (Alex) Liu
Hongqiang (Alex) Liu
Head of Intellectual Property Rights
Bayer Group Companies Greater China
Shuwen Xu
Shuwen Xu
Head of Legal Affairs Department
Guangzhou Baiyunshan Pharmaceutical
Xiangsheng Kong
Xiangsheng Kong
General Manager & IP Director
Livzon Pharmaceutical Group
Yunli Xue
Yunli Xue
Vice-President / General Manager
Luye Pharma Group/Shandong Luye
Allan Liu
Allan Liu
VP/Director BD Dept
Wanbang Biopharm/Fosun Pharmaceutical
Dieter Tzschoppe
Dieter Tzschoppe
Director Pure and Applied Organic Chemistry
European Patent Office (EPO)
Ann W. Chen
Ann W. Chen
Asia Regional IP Counsel
Eli Lilly and Company
Dr. David Shen
Dr. David Shen
Asia Area Legal Director
AstraZeneca
Ye Hua
Ye Hua
Senior Corporate Counsel, Intellectual Property; Senior Director/Regional patent counsel, China & EM Asia
Pfizer
Alka Mehta
Alka Mehta
Head IPR
Cipla
Haiyan Chen
Haiyan Chen
Senior Counsel (Patents)
GlaxoSmithKline
Alvin Deng
Alvin Deng
Patent & Licensing Manager
Novozymes
Jinyan Cao
Jinyan Cao
Senior Partner and Patent Attorney
Leading Intellectual Property Firm
Xiaoting Song
Xiaoting Song
Vice Dean of Law School, Tongji University;Director, Shanghai Intellectual Property Research Center of Traditional Chinese Medicine
Shanghai Intellectual Property Research Center of Traditional Chinese Medicine
Tuo Jin
Tuo Jin
Professor of Pharmacy and Director of the Intellectual Property Office
Shanghai Jiao Tong University
Ningling Wang
Ningling Wang
Managing partner
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Shanghai office
Sachiko Masuda
Sachiko Masuda
Assistant Professor, Graduate School of Pharmaceutical Sciences
University of Tokyo
Zhenfu Yuan
Zhenfu Yuan
Vice Director of IP School/ Executive Director
Shanghai University/ Shanghai Intellectual Property Academe
Hongyi Jiang
Hongyi Jiang
Senior Partner
LexField Law Offices
Ben Ni
Ben Ni
Head and Senior Director / Partnering and External Innovation (S&I, Asia Pacific)
Sanofi R&D
Xiaodong Zhang
Xiaodong Zhang
Associate Professor
East China University of Science and Technology
Xiujuan Chen
Xiujuan Chen
VP, Technology Marketing and Licensing/Sinoipro IP Management and Technology Transfer/Project Manager, The Office of Technology Transfer
SIBS, Chinese Academy of Sciences
Zhipei Jiang
Zhipei Jiang
Counsel/ Former Presiding Judge of Third Civil Division (IP)
King & Wood Mallesons/Supreme People's Court
 
 
Sponsor Opportunities
More exclusive sponsor opportunities, please CLICK HERE
Background
  • From the labor-intensive "Made in China" to knowledge-based "Created in China", China has embarked on an innovative journey to transform itself. However, to realize the transformation, there is a prerequisite, that is the Intellectual Property Right (IPR) protection. The tracker of emerging technologies says China is poised to surpass Japan as the second-largest spender on biomedical R&D, behind the U.S., as it sets far-ranging targets for new drug development as part of its 12th Five-Year Plan. The country's total R&D investments reached a cumulative $160 billion last year and are said to be paying off with exponential increases in pharmaceutical-related patent filings, according to a report issued by Lux Research. Unlike patents in other industries, pharmaceutical patents cover products that take a very long time to develop. It takes 10–15 years on average to develop a new medicine from the earliest stages of compound discovery to final approval. IP management has become the most important protection tool for R&D innovation and patent has been proved to be the primary driver of Pharma &Biotech corporate earnings.
  • 2013 Pharmaceutical Intellectual Property Forum (PIPF) is to be held on 27-28 November in Shanghai, China. This conference aims to provide a platform to facilitate exchange of experience, and encourage more cooperation between Pharmaceutical and Biotech Companies, Law firms and IP Agencies. You will walk away with fresh insights, tactics and tools to apply for patents, strategize your litigation techniques and remain competitive in today’s constantly changing patent landscape. Hear from experts, meet potential collaborators and gather insights to re-align your own IP strategy – only at 2013 Pharmaceutical Intellectual Property Forum (PIPF).
Why Should You Attend?
  • Learn about best practices and strategies in Pharma IP
  • Overcome the legal and regulatory challenges
  • Learn from best practices in IP litigations to help you devise your litigation strategy
  • Understand how to avoid patent infringements in clinical trials
  • Benefit from excellent networking opportunities with knowledgeable and experienced IP experts
  • The combination of broader, international perspectives and a deeper understanding of Chinese market

Who Should Attend?

By Company Types

 

By Job Title

 
Pharmaceutical Companies
Biotech companies
Medical devices companies
Academic & Research Institutions
Government Agencies
Intellectual Property Agencies
Law firms
Others
IP Director / Manager
Patent Director / Manager
R&D Director / Head
Patent Attorney
General Counsel/ Legal Counsel
In-house Lawyer
IP Counsel/IP Lawyer / Consultant
IP Investor
IP Owner
Media Partners